Durability of Radiofrequency Ablation in Barrett's Esophagus With Dysplasia

• DOI: 10.1053/j.gastro.2011.04.061
• Publication Date: 2011-05-08T01:13:25Z
• Authors: Nicholas J. Shaheen; Bergein F. Overholt; Richard E. Sampliner; Herbert C. Wolfsen; Kenneth K. Wang; David E. Fleischer; Virender K. Sharma; Glenn M. Eisen; M. Brian Fennerty; John G. Hunter; Mary P. Bronner; John R. Goldblum; Ana E. Bennett; Hiroshi Mashimo; Richard I. Rothstein; Stuart R. Gordon; Steven A. Edmundo...; Ryan D. Madanick; Anne F. Peery; V. Raman Muthusamy; Kenneth J. Chang; Michael B. Kimmey; Stuart J. Spechler; Ali A. Siddiqui; Rhonda F. Souza; Anthony Infantolino; John A. Dumot; Gary W. Falk; Joseph A. Galanko; Blair A. Jobe; Robert H. Hawes; Brenda J. Hoffman; Prateek Sharma; Amitabh Chak; Charles J. Lightdale
• Keywords: Male; Metaplasia; Esophageal Neoplasms; Kaplan-Meier Estimate; Adenocarcinoma; Middle Aged; Epithelium; 3. Good health; Barrett Esophagus; Esophagus; Treatment Outcome; Catheter Ablation; Disease Progression; Humans; Female; Esophagoscopy; Longitudinal Studies; Watchful Waiting; Precancerous Conditions; Aged

Radiofrequency ablation (RFA) can eradicate dysplasia and intestinal metaplasia in patients with dysplastic Barrett’s esophagus (BE), and reduce rates of esophageal adenocarcinoma. We assessed long-term rates of eradication, durability of neosquamous epithelium, disease progression, and safety of RFA in patients with dysplastic BE.